MCID: CYS014
MIFTS: 53

Cystadenocarcinoma

Categories: Cancer diseases, Endocrine diseases

Aliases & Classifications for Cystadenocarcinoma

MalaCards integrated aliases for Cystadenocarcinoma:

Name: Cystadenocarcinoma 12 56 45 15 17 74

Classifications:



External Ids:

Disease Ontology 12 DOID:3111
MeSH 45 D003536
NCIt 51 C2971
SNOMED-CT 69 21008007
UMLS 74 C0010631

Summaries for Cystadenocarcinoma

Disease Ontology : 12 An adenocarcinoma that derives from epithelial cells originating in glandular tissue, in which cystic accumulations of retained secretions are formed.

MalaCards based summary : Cystadenocarcinoma is related to bile duct cystadenocarcinoma and mucinous cystadenocarcinoma. An important gene associated with Cystadenocarcinoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Innate Immune System and HIV Life Cycle. The drugs Bevacizumab and Fluorouracil have been mentioned in the context of this disorder. Affiliated tissues include breast, pancreas and ovary, and related phenotypes are Decreased cell migration and Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance

Wikipedia : 77 Cystadenocarcinoma is a malignant form of a cystadenoma and is a cancer derived from glandular... more...

Related Diseases for Cystadenocarcinoma

Diseases related to Cystadenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 348)
# Related Disease Score Top Affiliating Genes
1 bile duct cystadenocarcinoma 33.1 CEACAM5 KRT7 MUC1 MUC2
2 mucinous cystadenocarcinoma 32.8 KRT7 MUC1 MUC16 MUC2 SLCO4A1 VIM
3 ovarian serous cystadenocarcinoma 32.2 AKT1 ERBB2 FBXW7 HRAS MUC16 PGR
4 serous cystadenocarcinoma 32.1 AKT1 ERBB2 ESR2 FBXW7 HRAS MUC16
5 papillary serous adenocarcinoma 31.7 KRT7 PGR TP53
6 cystadenoma 31.0 KRT7 MUC1 MUC2 PGR
7 pseudomyxoma peritonei 30.5 KRT7 MUC1 MUC2 TP53
8 leiomyosarcoma 30.2 PGR TP53 VIM
9 polymorphous low-grade adenocarcinoma 30.1 CEACAM3 MUC1 VIM
10 mucinous adenocarcinoma 30.1 KRT7 MUC1 MUC2
11 adenocarcinoma 30.1 AKT1 ERBB2 HRAS MUC1 PIK3CA TP53
12 cystic teratoma 30.1 KRT7 MUC2 TP53
13 adenosquamous carcinoma 30.0 KRT7 MUC1 PIK3CA TP53
14 dermoid cyst 29.9 KRT7 MUC1 PGR VIM
15 endosalpingiosis 29.9 KRT7 MUC1 PGR
16 leiomyoma 29.8 ESR2 PGR VIM
17 appendix cancer 29.6 KRT7 MUC1 MUC2 TP53
18 pancreatic ductal carcinoma 29.6 KRT7 MUC1 MUC2 TP53
19 squamous cell carcinoma 29.6 AKT1 ERBB2 HRAS MUC1 PIK3CA TP53
20 transitional cell carcinoma 29.6 ERBB2 HRAS KRT7 TP53
21 mucinous ovarian cystadenoma 29.6 CEACAM5 KRT7 MUC1
22 intrahepatic cholangiocarcinoma 29.6 KRT7 MUC1 MUC2 TP53
23 sclerosing hemangioma 29.6 KRT7 MUC1 PGR
24 breast adenocarcinoma 29.5 AKT1 ERBB2 PIK3CA PPP2R1A TP53
25 polycystic liver disease 1 with or without kidney cysts 29.1 CEACAM3 CEACAM5 KRT7 MUC1 MUC16
26 carcinosarcoma 29.1 ERBB2 HRAS KRT7 MUC1 PGR PIK3CA
27 ovarian cancer 1 28.9 AKT1 CEACAM5 ERBB2 KRT7 PIK3CA TP53
28 pancreatic cancer 28.4 AKT1 CEACAM3 CEACAM5 ERBB2 HRAS MUC1
29 papillary adenocarcinoma 28.4 CEACAM5 ERBB2 KRT7 MUC1 MUC16 MUC2
30 cholangiocarcinoma 28.2 AKT1 CEACAM3 CEACAM5 ERBB2 KRT7 MUC1
31 endometrial cancer 28.0 AKT1 ERBB2 ESR2 HRAS KRT7 MUC16
32 ovarian cancer 27.8 AKT1 ERBB2 ESR2 KRT7 MUC1 MUC16
33 breast cancer 27.8 AKT1 CEACAM5 ERBB2 ESR2 FBXW7 HRAS
34 papillary cystadenocarcinoma 12.5
35 ovarian mucinous cystadenocarcinoma 12.5
36 pancreatic serous cystadenocarcinoma 12.5
37 ovarian cystadenocarcinoma 12.3
38 lung mucinous cystadenocarcinoma 12.3
39 ovarian clear cell cystadenocarcinoma 12.3
40 pancreatic cystadenocarcinoma 12.2
41 acinar cell cystadenocarcinoma 12.2
42 mucinous cystadenocarcinoma of the pancreas 12.2
43 appendix mucinous cystadenocarcinoma 12.1
44 breast mucinous cystadenocarcinoma 12.0
45 pancreatic non-invasive mucinous cystadenocarcinoma 12.0
46 pancreatic colloid cystadenocarcinoma 12.0
47 pancreatic invasive mucinous cystadenocarcinoma 12.0
48 appendix adenocarcinoma 11.5
49 multilocular clear cell renal cell carcinoma 11.2
50 multilocular cystic renal neoplasm of low malignant potential 11.0

Graphical network of the top 20 diseases related to Cystadenocarcinoma:



Diseases related to Cystadenocarcinoma

Symptoms & Phenotypes for Cystadenocarcinoma

GenomeRNAi Phenotypes related to Cystadenocarcinoma according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased cell migration GR00055-A-1 9.35 AKT1 HRAS MUC1 PIK3CA VIM
2 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.02 ERBB2 HRAS MUC1 PPP2R1A VIM

MGI Mouse Phenotypes related to Cystadenocarcinoma:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.16 AKT1 ERBB2 ESR2 FBXW7 HRAS MUC2
2 homeostasis/metabolism MP:0005376 10.15 AKT1 ERBB2 ESR2 FBXW7 HRAS KRT7
3 cellular MP:0005384 10.13 AKT1 ERBB2 ESR2 FBXW7 KRT7 MUC2
4 endocrine/exocrine gland MP:0005379 10.06 AKT1 ERBB2 ESR2 FBXW7 HRAS MUC2
5 integument MP:0010771 9.92 AKT1 ERBB2 ESR2 FBXW7 HRAS PGR
6 neoplasm MP:0002006 9.85 AKT1 ERBB2 ESR2 FBXW7 HRAS MUC2
7 muscle MP:0005369 9.8 AKT1 ERBB2 ESR2 PGR PIK3CA TP53
8 normal MP:0002873 9.56 AKT1 ERBB2 ESR2 FBXW7 HRAS PGR
9 respiratory system MP:0005388 9.17 AKT1 ERBB2 ESR2 FBXW7 HRAS TP53

Drugs & Therapeutics for Cystadenocarcinoma

Drugs for Cystadenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 243)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 216974-75-3
2
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
3
Oxaliplatin Approved, Investigational Phase 3,Phase 2,Phase 1 61825-94-3 43805 6857599 5310940 9887054
4
Cetuximab Approved Phase 3,Phase 2,Phase 1,Early Phase 1 205923-56-4 56842117 2333
5
Capecitabine Approved, Investigational Phase 3,Phase 2,Phase 1 154361-50-9 60953
6
Levoleucovorin Approved, Investigational Phase 3,Phase 2,Phase 1 68538-85-2
7
leucovorin Approved Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 143 6006
8
Irinotecan Approved, Investigational Phase 3,Phase 2,Phase 1 100286-90-6, 97682-44-5 60838
9
Cobalt Approved, Experimental Phase 3 7440-48-4 104729
10
Carboplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 10339178 38904 498142
11
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 33069-62-4 36314
12
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
13
Everolimus Approved Phase 2, Phase 3,Phase 1 159351-69-6 70789204 6442177
14
Letrozole Approved, Investigational Phase 2, Phase 3,Phase 3 112809-51-5 3902
15
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 1 22916-47-8 4189
16
Sirolimus Approved, Investigational Phase 2, Phase 3,Phase 1 53123-88-9 46835353 5284616 6436030
17
Cisplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 2767 441203 84093
18
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
19
Topotecan Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 119413-54-6, 123948-87-8 60700
20
Docetaxel Approved, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124
21
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
22
Gemcitabine Approved Phase 2, Phase 3,Phase 3,Phase 1 95058-81-4 60750
23
Olaparib Approved Phase 2, Phase 3,Phase 1,Early Phase 1 763113-22-0 23725625
24
Metformin Approved Phase 2, Phase 3,Phase 1 657-24-9 14219 4091
25
Sodium Citrate Approved, Investigational Phase 2, Phase 3 68-04-2
26
Trametinib Approved Phase 2, Phase 3,Phase 1 871700-17-3 11707110
27
Tamoxifen Approved Phase 2, Phase 3 10540-29-1 2733526
28
Pembrolizumab Approved Phase 3,Phase 2 1374853-91-4
29
Atezolizumab Approved, Investigational Phase 2, Phase 3 1380723-44-3
30
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
31
Calcium Approved, Nutraceutical Phase 3,Phase 2,Phase 1,Early Phase 1 7440-70-2 271
32
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 59-30-3 6037
33
Glutamic Acid Approved, Nutraceutical Phase 3,Phase 1 56-86-0 33032
34
Citric Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 77-92-9 311
35
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
36 Edrecolomab Experimental, Investigational Phase 3 156586-89-9
37
Camptothecin Experimental Phase 3 7689-03-4
38
Cediranib Investigational Phase 2, Phase 3,Phase 1 288383-20-0 9933475
39
Maleic acid Experimental, Investigational Phase 2, Phase 3,Phase 1 110-17-8, 110-16-7 444972
40 Paclitaxel poliglumex Experimental, Investigational Phase 3,Phase 1 263351-82-2
41 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
42 Cola Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
43 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
44 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
45 Antidotes Phase 3,Phase 2,Phase 1
46 Antimetabolites Phase 3,Phase 2,Phase 1
47 Antineoplastic Agents, Immunological Phase 3,Phase 2,Phase 1,Early Phase 1
48 Hormones Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
49 Nutrients Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
50 Vitamin B Complex Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 208)
# Name Status NCT ID Phase Drugs
1 Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer Unknown status NCT01167725 Phase 3 FOLFIRI regimen;FOLFOX regimen;capecitabine;fluorouracil;irinotecan hydrochloride;leucovorin calcium;mitomycin C;oxaliplatin
2 Radiation Therapy Plus Chemotherapy Before Surgery With or Without Chemotherapy After Surgery in Treating Patients With Rectal Cancer Unknown status NCT00002896 Phase 3 chemotherapy;fluorouracil;leucovorin calcium
3 Edrecolomab in Treating Patients With Stage II Colon Cancer Completed NCT00002968 Phase 3
4 High-Dose Fluorouracil With or Without Leucovorin Compared With Standard Fluorouracil Plus Leucovorin Following Surgery in Treating Patients With Stage III Colon Cancer Completed NCT00004150 Phase 3 fluorouracil;leucovorin calcium
5 Irinotecan Compared With Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer Completed NCT00005036 Phase 3 irinotecan hydrochloride;oxaliplatin;leucovorin calcium;fluorouracil
6 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed NCT00262847 Phase 3 Carboplatin;Paclitaxel
7 Comparison of Adjuvant Chemotherapy Regimens in Treating Stage II/III Rectal Cancer Completed NCT00068692 Phase 3 Fluorouracil;Leucovorin Calcium;Oxaliplatin;Irinotecan
8 Combination Chemotherapy With or Without Surgery in Treating Patients With Stage III Ovarian Epithelial Cancer Completed NCT00002568 Phase 3 cisplatin;paclitaxel
9 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer Completed NCT00483782 Phase 3 carboplatin;paclitaxel
10 Paclitaxel and Cisplatin in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer Completed NCT00002717 Phase 3 cisplatin;paclitaxel
11 Combination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian Cancer Completed NCT00003322 Phase 3 cisplatin;paclitaxel
12 Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer Completed NCT00003644 Phase 3 carboplatin;paclitaxel
13 Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer Completed NCT00006011 Phase 3 Doxorubicin Hydrochloride;Cisplatin;Paclitaxel
14 Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT00719303 Phase 3
15 Trial of Cisplatin Plus Radiation Followed by Carbo and Taxol Vs. Sandwich Therapy of Carbo and Taxol Followed Radiation Then Further Carbo and Taxol Recruiting NCT02501954 Phase 3 Cisplatin;Carboplatin;Paclitaxel
16 Short Course Vaginal Cuff Brachytherapy in Treating Patients With Stage I-II Endometrial Cancer Recruiting NCT03422198 Phase 3
17 Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02502266 Phase 2, Phase 3 Cediranib Maleate;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan Hydrochloride
18 Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Active, not recruiting NCT00951496 Phase 3 Carboplatin;Carboplatin;Cisplatin;Paclitaxel;Paclitaxel
19 Treatment Plan for an Individual Patient With Recurrent Uterine Papillary Serous Carcinoma (UPSC) With PIK3CA Gene Mutation Active, not recruiting NCT03285802 Phase 2, Phase 3 Letrozole;Everolimus
20 Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer Active, not recruiting NCT01081262 Phase 3 Capecitabine;Carboplatin;Oxaliplatin;Paclitaxel
21 Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Active, not recruiting NCT00565851 Phase 3 Carboplatin;Docetaxel;Gemcitabine Hydrochloride;Paclitaxel
22 Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Active, not recruiting NCT01167712 Phase 3 Carboplatin;Paclitaxel
23 Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer Active, not recruiting NCT00108745 Phase 3 Paclitaxel;Paclitaxel Poliglumex
24 Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer Active, not recruiting NCT00217737 Phase 3 Fluorouracil;Leucovorin Calcium;Oxaliplatin
25 Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer Active, not recruiting NCT00942357 Phase 3 Carboplatin;Cisplatin;Paclitaxel
26 Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer Active, not recruiting NCT02101788 Phase 2, Phase 3 Letrozole;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Tamoxifen Citrate;Topotecan Hydrochloride;Trametinib
27 Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer Active, not recruiting NCT02065687 Phase 2, Phase 3 Carboplatin;Metformin Hydrochloride;Paclitaxel
28 Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer Active, not recruiting NCT00807768 Phase 3 Carboplatin;Paclitaxel
29 Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer Not yet recruiting NCT03914612 Phase 3 Carboplatin;Paclitaxel
30 Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Suspended NCT02839707 Phase 2, Phase 3 Atezolizumab;Pegylated Liposomal Doxorubicin Hydrochloride
31 Paclitaxel Plus Carboplatin With or Without SCH-58500 in Treating Patients With Newly Diagnosed Stage III Ovarian or Stage III Primary Peritoneal Cancer Terminated NCT00003880 Phase 2, Phase 3 carboplatin;paclitaxel
32 Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Persistent Ovarian Epithelial Cancer Terminated NCT00002819 Phase 3 carboplatin;cyclophosphamide;mitoxantrone hydrochloride;paclitaxel
33 Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy Withdrawn NCT01492920 Phase 3
34 Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer Unknown status NCT02283658 Phase 2 Everolimus;Letrozole
35 Paclitaxel and Intraperitoneal Carboplatin Followed by Radiation Therapy in Treating Patients With Stage IIIC-IV Uterine Cancer Unknown status NCT02112552 Phase 2 Paclitaxel;Carboplatin
36 VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer Unknown status NCT01666444 Phase 2 pegylated liposomal doxorubicin (PLD);VTX-2337;Placebo
37 Combination Chemotherapy Plus IM-862 in Treating Patients With Resected Stage III Ovarian Cancer or Primary Peritoneal Cancer Unknown status NCT00017303 Phase 2 carboplatin;oglufanide disodium;paclitaxel
38 Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer Completed NCT01196429 Phase 2 Carboplatin;Docetaxel;Paclitaxel;Temsirolimus
39 Treatment of Peritoneal Cancer With Surgery, Perfused Heated Cisplatin and Chemotherapy Completed NCT00004547 Phase 2 Postoperative dwell with paclitaxel and 5-FU
40 Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin Completed NCT00993616 Phase 2 belinostat;carboplatin
41 A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed NCT00939809 Phase 2
42 Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy Completed NCT00466960 Phase 2 paclitaxel albumin-stabilized nanoparticle formulation
43 Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma Completed NCT00059787 Phase 2 paclitaxel;carboplatin;erlotinib
44 Papillary Serous Carcinoma of the Endometrium Completed NCT00515073 Phase 2 Paclitaxel;Dexamethasone;Cimetidine;Diphenhydramine
45 Gleevec/Taxol for Patients With Uterine Papillary Serous Carcinoma Completed NCT00506779 Phase 1, Phase 2 Imatinib Mesylate;Paclitaxel
46 A Study of Radiation Therapy and Paclitaxel and Carboplatin in Patients With Uterine Papillary Serous Carcinoma Completed NCT00231868 Phase 2 Carboplatin and Paclitaxel and Pelvic Radiation Therapy;Carboplatin and Paclitaxel and Radiation Therapy
47 Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT01225887 Phase 2 Nintedanib
48 Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT01642082 Phase 2
49 Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT00888173 Phase 2 Brivanib Alaninate
50 Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer Completed NCT00100841 Phase 2 oxaliplatin;leucovorin calcium;fluorouracil

Search NIH Clinical Center for Cystadenocarcinoma

Cochrane evidence based reviews: cystadenocarcinoma

Genetic Tests for Cystadenocarcinoma

Anatomical Context for Cystadenocarcinoma

MalaCards organs/tissues related to Cystadenocarcinoma:

42
Breast, Pancreas, Ovary, Liver, Colon, Appendix, Lung

Publications for Cystadenocarcinoma

Articles related to Cystadenocarcinoma:

(show top 50) (show all 796)
# Title Authors Year
1
Concomitant adenosquamous carcinoma and cystadenocarcinoma of the extrahepatic bile duct: A case report. ( 30705898 )
2019
2
Unilateral renal cystadenocarcinoma and nodular dermatofibrosis in a mixed-breed dog carrying a FLCN gene mutation. ( 30672048 )
2019
3
Urachal Mucinous Cystadenocarcinoma. ( 30674499 )
2019
4
MRI Findings of Borderline Retroperitoneal Serous Cystadenocarcinoma. ( 30823957 )
2019
5
The rare entity of cystadenocarcinoma (CAC) in parotid gland: A single-center experience. ( 30857928 )
2019
6
High-grade Features of Papillary Cystadenocarcinoma of the Parotid Gland. ( 30918612 )
2019
7
Laparoscopy-assisted extended right hepatectomy for giant hemorrhagic hepatic cyst mimicking biliary cystadenocarcinoma: a case report. ( 30977012 )
2019
8
Mucinous cystadenocarcinoma in the renal pelvis: primary or secondary? Case report and literature review. ( 31084406 )
2019
9
Contrast-enhanced Harmonic EUS Imaging of Pancreatic Mucinous Cystadenocarcinoma. ( 29780137 )
2018
10
Mucinous cystadenocarcinoma arising from mucinous cystadenoma of the lung: case report and review of the literature. ( 29850162 )
2018
11
Cystadenocarcinoma of the mandible. ( 29900928 )
2018
12
A Network Pharmacology-Based Analysis of Multi-Target, Multi-Pathway, Multi-Compound Treatment for Ovarian Serous Cystadenocarcinoma. ( 30097905 )
2018
13
Gastric metastasis of ovarian serous cystadenocarcinoma. ( 30233254 )
2018
14
Bilateral Breast and Axillary Lymph Nodes Metastases of an Ovarian Serous Cystadenocarcinoma. ( 30287996 )
2018
15
Appendiceal mucinous cystadenocarcinoma with mural nodules of anaplastic carcinoma and K-RAS mutation. ( 30289401 )
2018
16
Hepatic Sclerosing Hemangioma with Predominance of the Sclerosed Area Mimicking a Biliary Cystadenocarcinoma. ( 30402303 )
2018
17
A five-DNA methylation signature act as a novel prognostic biomarker in patients with ovarian serous cystadenocarcinoma. ( 30446011 )
2018
18
Hepatobiliary Mucinous Cystic Neoplasms With Ovarian Type Stroma (So-Called "Hepatobiliary Cystadenoma/Cystadenocarcinoma"): Clinicopathologic Analysis of 36 Cases Illustrates Rarity of Carcinomatous Change. ( 29016404 )
2018
19
Two protein-coding genes act as a novel clinical signature to predict prognosis in patients with ovarian serous cystadenocarcinoma. ( 29456732 )
2018
20
High-grade metastatic paratesticular cystadenocarcinoma. ( 29541584 )
2018
21
Mucinous Cystadenocarcinoma of the Breast: Report of 2 Cases Including One With Long-Term Local Recurrence. ( 29745281 )
2018
22
Acinar Cell Cystadenocarcinoma of the Pancreas. ( 29033770 )
2017
23
Contrast enhanced ultrasound features of hepatic cystadenoma and hepatic cystadenocarcinoma. ( 27887203 )
2017
24
Pulmonary Mucinous Cystadenocarcinoma Presenting as Extensive Multifocal Cystic Lesions. ( 28199793 )
2017
25
Expression of Yes-associated protein 1 and its clinical significance in ovarian serous cystadenocarcinoma. ( 28339095 )
2017
26
Mucinous cystadenocarcinoma of ovary with metastasis in 14-year-old girl. ( 28344967 )
2017
27
Pancreatic pseudocyst or mucinous cystadenocarcinoma of pancreas? A diagnostic dilemma. ( 28396777 )
2017
28
Pseudomyxoma Peritonei as a First Manifestation of KRAS-Mutated Urachal Mucinous Cystadenocarcinoma of the Bladder: A Case Report. ( 28449606 )
2017
29
Serous cystadenocarcinoma of the spleen. ( 28491168 )
2017
30
Low-grade Cribriform Cystadenocarcinoma: A Review of the Literature and Case Report. ( 28507867 )
2017
31
Low-grade intraductal carcinoma (low-grade cribriform cystadenocarcinoma) with tumor-associated lymphoid proliferation of parotid gland. ( 28551385 )
2017
32
Biliary Cystadenoma and Cystadenocarcinoma of the Gallbladder: A Clinical Review. ( 28637540 )
2017
33
High Grade Serous Cystadenocarcinoma of Testis-Case Report of a Rare Ovarian Epithelial Type Tumour. ( 28764180 )
2017
34
18F-FDG PET/CT Imaging of Pulmonary Mucinous Cystadenocarcinoma with Signet Ring Cells. ( 28878858 )
2017
35
Clinicopathological features and post-resection outcomes of biliary cystadenoma and cystadenocarcinoma of the liver. ( 28989996 )
2017
36
Mucinous cystadenocarcinoma of the breast: the challenge of diagnosing a rare entity. ( 29081926 )
2017
37
Papillary cystadenocarcinoma of the sublingual gland. ( 29124004 )
2017
38
The long-term survival in primary retroperitoneal mucinous cystadenocarcinoma: a case report. ( 29177806 )
2017
39
A Case Report of Partial Nephrectomy of Mucinous Cystadenocarcinoma in Kidney and Its Literature Review. ( 25687861 )
2016
40
EDUCATION AND IMAGING. Hepatobiliary and Pancreatic: Long-term survival of serous cystadenocarcinoma of the pancreas with synchronous liver metastases after aggressive surgical resection. ( 26177796 )
2016
41
Cystadenocarcinoma of the salivary glands with potential lymph node metastasis. ( 26441367 )
2016
42
Primary retroperitoneal mucinous cystadenocarcinoma (PRMCa): a systematic review of the literature and meta-analysis. ( 26681306 )
2016
43
Cytology of low-grade cribriform cystadenocarcinoma in salivary glands: Cytological and immunohistochemical distinctions from other salivary gland neoplasms. ( 26875597 )
2016
44
Hepatobiliary and Pancreatic: Degenerative hepatic hemangioma mimicking biliary cystadenocarcinoma. ( 26896817 )
2016
45
A giant mucinous cystadenocarcinoma of the appendix: a case report and review of the literature. ( 26945579 )
2016
46
Serous Cystadenocarcinoma of the Pancreas: Clinical Features and Management of a Rare Tumor. ( 26998825 )
2016
47
Vaginal fold prolapse in a dog with pyometra and ovarian papillary cystadenocarcinoma. ( 27003024 )
2016
48
Low-grade cribriform cystadenocarcinoma arising from a minor salivary gland: a case report. ( 27021553 )
2016
49
Rare biliary cystic tumors: a case series of biliary cystadenomas and cystadenocarcinoma. ( 27049501 )
2016
50
Single nucleotide polymorphisms in glutathione S-transferase P1 and M1 genes and overall survival of patients with ovarian serous cystadenocarcinoma treated with chemotherapy. ( 27073511 )
2016

Variations for Cystadenocarcinoma

Expression for Cystadenocarcinoma

Search GEO for disease gene expression data for Cystadenocarcinoma.

Pathways for Cystadenocarcinoma

Pathways related to Cystadenocarcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 70)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.92 AKT1 CEACAM3 ERBB2 FBXW7 HRAS MUC1
2
Show member pathways
13.71 AKT1 ERBB2 FBXW7 HRAS MUC1 MUC16
3
Show member pathways
13.46 AKT1 ERBB2 FBXW7 HRAS PIK3CA PPP2R1A
4
Show member pathways
13.32 AKT1 CEACAM3 CEACAM5 HRAS PIK3CA PPP2R1A
5
Show member pathways
13.3 AKT1 ERBB2 HRAS MUC1 PIK3CA PPP2R1A
6
Show member pathways
13.04 AKT1 ESR2 HRAS PGR PIK3CA PPP2R1A
7
Show member pathways
13 AKT1 ERBB2 HRAS PIK3CA PPP2R1A TP53
8
Show member pathways
12.87 AKT1 ERBB2 HRAS PIK3CA TP53
9 12.81 AKT1 ERBB2 ESR2 HRAS PIK3CA TP53
10
Show member pathways
12.73 AKT1 ERBB2 HRAS PIK3CA TP53
11
Show member pathways
12.64 AKT1 ERBB2 HRAS PIK3CA PPP2R1A TP53
12
Show member pathways
12.61 AKT1 ERBB2 ESR2 HRAS PIK3CA TP53
13
Show member pathways
12.59 AKT1 ERBB2 HRAS PIK3CA TP53
14
Show member pathways
12.56 AKT1 HRAS PIK3CA VIM
15
Show member pathways
12.56 AKT1 ERBB2 HRAS PIK3CA TP53
16 12.53 ERBB2 HRAS PIK3CA TP53 VIM
17
Show member pathways
12.5 AKT1 ERBB2 HRAS PIK3CA TP53
18
Show member pathways
12.48 AKT1 ERBB2 ESR2 HRAS PIK3CA
19
Show member pathways
12.44 HRAS MUC1 MUC16 MUC2
20
Show member pathways
12.4 AKT1 HRAS PIK3CA TP53
21
Show member pathways
12.38 AKT1 HRAS PIK3CA PPP2R1A TP53
22
Show member pathways
12.38 AKT1 ERBB2 HRAS PIK3CA TP53
23
Show member pathways
12.37 AKT1 ERBB2 HRAS MUC1 PIK3CA TP53
24 12.36 AKT1 HRAS PIK3CA TP53
25
Show member pathways
12.36 AKT1 PGR PIK3CA PPP2R1A
26
Show member pathways
12.33 AKT1 ERBB2 HRAS PIK3CA
27
Show member pathways
12.32 AKT1 HRAS PIK3CA TP53
28
Show member pathways
12.24 CEACAM3 CEACAM5 HRAS PIK3CA
29
Show member pathways
12.22 AKT1 ERBB2 ESR2 HRAS PIK3CA
30
Show member pathways
12.22 AKT1 ERBB2 ESR2 HRAS MUC2 PGR
31 12.19 AKT1 HRAS PIK3CA TP53
32
Show member pathways
12.18 AKT1 HRAS PIK3CA TP53
33 12.18 AKT1 ERBB2 HRAS PIK3CA TP53
34
Show member pathways
12.16 AKT1 ERBB2 HRAS PIK3CA TP53
35
Show member pathways
12.15 AKT1 ERBB2 HRAS PIK3CA
36
Show member pathways
12.15 AKT1 HRAS PIK3CA TP53
37
Show member pathways
12.13 AKT1 ERBB2 HRAS PIK3CA
38
Show member pathways
12.05 AKT1 ERBB2 PIK3CA TP53
39 12 AKT1 HRAS PIK3CA TP53
40 11.99 AKT1 ERBB2 HRAS PIK3CA TP53
41 11.98 AKT1 MUC1 TP53 VIM
42 11.96 AKT1 HRAS TP53
43 11.93 AKT1 PIK3CA PPP2R1A
44
Show member pathways
11.93 ERBB2 HRAS PGR PIK3CA
45 11.92 AKT1 ERBB2 PIK3CA
46 11.91 AKT1 HRAS PIK3CA
47 11.88 AKT1 PIK3CA TP53
48
Show member pathways
11.88 AKT1 HRAS PIK3CA
49 11.84 AKT1 HRAS PIK3CA PPP2R1A TP53
50
Show member pathways
11.81 AKT1 HRAS PIK3CA

GO Terms for Cystadenocarcinoma

Cellular components related to Cystadenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 9.4 AKT1 CEACAM3 CEACAM5 ERBB2 HRAS MUC1
2 Golgi lumen GO:0005796 9.13 MUC1 MUC16 MUC2

Biological processes related to Cystadenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 9.67 AKT1 FBXW7 HRAS PGR
2 positive regulation of gene expression GO:0010628 9.65 AKT1 ERBB2 HRAS TP53 VIM
3 O-glycan processing GO:0016266 9.5 MUC1 MUC16 MUC2
4 negative regulation of macroautophagy GO:0016242 9.46 AKT1 PIK3CA
5 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.43 MUC1 TP53
6 anoikis GO:0043276 9.4 AKT1 PIK3CA
7 cytokine-mediated signaling pathway GO:0019221 9.35 AKT1 MUC1 PIK3CA TP53 VIM
8 phosphatidylinositol 3-kinase signaling GO:0014065 9.33 AKT1 ERBB2 PIK3CA
9 stimulatory C-type lectin receptor signaling pathway GO:0002223 8.92 HRAS MUC1 MUC16 MUC2

Molecular functions related to Cystadenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.23 AKT1 CEACAM5 ERBB2 ESR2 FBXW7 PGR

Sources for Cystadenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....